29 results
8-K
COCP
Cocrystal Pharma Inc
20 Jul 18
Entry into a Material Definitive Agreement
4:50pm
.
Ladenburg has a “conflict of interest” within the meaning of Financial Industry Regulatory Authority (“FINRA”) Rule 5121(f)(5)(B) in this offering … to this conflict of interest, Barrington Research is acting as a “qualified independent underwriter” in accordance with FINRA Rule 5121.
The Shares
8-K
COCP
Cocrystal Pharma Inc
26 Mar 19
Entry into a Material Definitive Agreement
5:13pm
with FINRA Rule 5121, due to Ladenburg’s conflict of interest resulting from the beneficial ownership by Dr. Phillip Frost, a director of the Company
8-K
EX-3.1
COCP
Cocrystal Pharma Inc
19 Feb 21
Amendments to Articles of Incorporation or Bylaws
8:30am
of an asserted conflict of interest or otherwise.
Section 9. Removal of Directors. At a meeting of the stockholders called expressly … circumstances, and whether the proposed transaction presents an improper conflict of interest for any officer or director of the Company, whether
424B5
COCP
Cocrystal Pharma Inc
20 Jul 18
Prospectus supplement for primary offering
4:46pm
to be received in any escrow, trust or similar arrangement.
Ladenburg has a “conflict of interest” within the meaning of Financial Industry Regulatory … of Ladenburg Thalmann Financial Services, Inc. Due to this conflict of interest, Barrington Research is acting as a “qualified independent underwriter
8-K
EX-10.2
0ysc01 mr
4 Mar 20
Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market
5:09pm
8-K
EX-3.4
apk v04vzxrr9
1 Dec 14
Entry into a Material Definitive Agreement
12:00am
8-K
EX-10.7
29tc9g1bas
1 Mar 11
Departure of Directors or Certain Officers
12:00am
8-K
EX-3.6
nmpqwwlqs8ua1
1 Dec 14
Entry into a Material Definitive Agreement
12:00am
8-K
EX-1.1
u9as6eor
20 Jul 18
Entry into a Material Definitive Agreement
4:50pm
8-K
EX-99.2
jjc063
2 Oct 20
Other Events
8:00am